{'52WeekChange': 4.599091,
 'SandP52WeekChange': None,
 'address1': '555 Long Wharf Drive',
 'address2': '12th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 62.23,
 'askSize': 1800,
 'averageDailyVolume10Day': 786062,
 'averageVolume': 507798,
 'averageVolume10days': 786062,
 'beta': 2.104931,
 'beta3Year': None,
 'bid': 60.72,
 'bidSize': 1200,
 'bookValue': 3.597,
 'category': None,
 'circulatingSupply': None,
 'city': 'New Haven',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 62.18,
 'dayLow': 58.51,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -28.019,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1149112320,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '475 238 6837',
 'fiftyDayAverage': 53.596855,
 'fiftyTwoWeekHigh': 71.5,
 'fiftyTwoWeekLow': 3.76,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 10720678,
 'forwardEps': -3.13,
 'forwardPE': -19.41214,
 'fromCurrency': None,
 'fullTimeEmployees': 27,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.48511,
 'heldPercentInstitutions': 0.28522,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/bioxceltherapeutics.com',
 'longBusinessSummary': 'BioXcel Therapeutics, Inc., a clinical stage '
                        'biopharmaceutical company, focuses on novel '
                        'artificial intelligence-based drug development in the '
                        'fields of neuroscience and immuno-oncology in the '
                        'United States. The company is involved in developing '
                        'BXCL501, a sublingual thin film formulation of '
                        'dexmedetomidine for acute treatment of agitation '
                        'resulting from neurological and psychiatric '
                        'disorders; and BXCL701, an immuno-oncology agent for '
                        'the treatment of prostate and pancreatic cancers, and '
                        'other solid tumors. BioXcel Therapeutics, Inc. has a '
                        'collaboration with Merck KGaA; Nektar Therapeutics, '
                        'Inc.; and Pfizer Inc. to develop a therapy for '
                        'treating pancreatic cancer. The company was founded '
                        'in 2017 and is headquartered in New Haven, '
                        'Connecticut. BioXcel Therapeutics, Inc. is a '
                        'subsidiary of BioXcel Corporation.',
 'longName': 'BioXcel Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1228038528,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_543567629',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -40675000,
 'nextFiscalYearEnd': 1640908800,
 'open': 60.06,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.28,
 'phone': '475 238 6837',
 'previousClose': 61.59,
 'priceHint': 2,
 'priceToBook': 16.891855,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 62.18,
 'regularMarketDayLow': 58.51,
 'regularMarketOpen': 60.06,
 'regularMarketPreviousClose': 61.59,
 'regularMarketPrice': 60.06,
 'regularMarketVolume': 450544,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 20211300,
 'sharesPercentSharesOut': 0.1108,
 'sharesShort': 2238658,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 674784,
 'shortName': 'BioXcel Therapeutics, Inc.',
 'shortPercentOfFloat': 0.21290001,
 'shortRatio': 4.42,
 'startDate': None,
 'state': 'CT',
 'strikePrice': None,
 'symbol': 'BTAI',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.377,
 'twoHundredDayAverage': 34.82921,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'ed3396e0-a498-379a-b23a-cf6795d0f871',
 'volume': 450544,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.bioxceltherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '06511'}